Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corp (NASDAQ: OPRX) provides a dedicated news hub for tracking developments in healthcare technology and digital patient engagement solutions. This page aggregates official announcements, financial disclosures, and strategic updates from the leader in EHR-integrated pharma messaging.
Investors and industry professionals will find curated coverage of earnings reports, technology partnerships, product launches, and regulatory milestones. The resource serves as a centralized source for understanding OPRX's role in connecting pharmaceutical companies with healthcare providers through cloud-based communication platforms.
Key content categories include financial results, strategic alliances with EHR providers, technology innovations in digital health messaging, and industry recognition of platform advancements. All materials maintain factual accuracy and timeliness required for informed decision-making.
Bookmark this page for streamlined access to OptimizeRx's evolving position in medication adherence solutions and AI-driven healthcare communications. Regular updates ensure stakeholders stay informed about developments impacting the digital pharma marketing landscape.
OptimizeRx Corp. (Nasdaq: OPRX) has launched an innovative enhancement to its digital health platform that utilizes real-world data (RWD) and machine learning to deliver therapeutic support directly to clinicians at critical patient care moments. This unprecedented approach aims to improve communication and data accessibility in healthcare, potentially enhancing patient outcomes, especially in complex cases like oncology. OptimizeRx emphasizes the importance of actionable data for effective treatment decisions and aims to improve healthcare systems through its AI-driven capabilities.
OptimizeRx Corp. (Nasdaq: OPRX) has reported a remarkable 217% revenue growth from 2016 to 2019, attributed to its expanding digital health platform. The company earned the 432nd spot on Deloitte’s Technology Fast 500, recognizing fast-growing tech companies in North America. CEO William Febbo emphasized the significance of their digital health solutions and a dedicated team. The recent record revenue of $10.5 million for Q3 2020, reflecting a 110% increase year-over-year, signals continued strong performance in a growing market.
OptimizeRx Corp. (Nasdaq: OPRX) has partnered with Fierce Life Sciences to host a virtual event, Innovate4Outcomes, on December 3, 2020. The event aims to address key healthcare challenges exacerbated by COVID-19, promoting collaboration among industry leaders to enhance patient outcomes. Discussions will focus on supporting providers, the role of clinicians in digital strategies, adoption of patient support programs, and leveraging social media for patient engagement. Attendance is limited to 100 participants.
OptimizeRx Corp. (Nasdaq: OPRX) has appointed Angelo Campano as senior vice president and principal of agency channels to enhance partnerships with healthcare advertising agencies. With over 15 years of experience, Campano aims to drive strategic growth at OptimizeRx, including implementing point-of-care engagement programs for targeted patient populations. His background includes significant achievements in electronic health record (EHR) workflows and marketing at Ogilvy Health. The company's digital health platform connects life sciences with healthcare providers, facilitating medication affordability for patients.
OptimizeRx Corp. (Nasdaq: OPRX) reported significant financial growth for Q3 2020, with revenue increasing by 110% to $10.5 million and gross profit up 99% to $6.0 million. Non-GAAP net income was $1.1 million or $0.07 per share. The cash balance was $12.0 million, down from $14.1 million due to higher working capital investments. The company closed additional enterprise deals worth $3.6 million and expanded its digital health network through partnerships with Higi and Epion Health. Despite a GAAP net loss of $0.3 million, management remains optimistic about future growth.
OptimizeRx Corp. (Nasdaq: OPRX) will host a conference call on November 9, 2020, to discuss its Q3 2020 results, expecting record revenue exceeding $10 million, a 100% increase from the previous year. The call will also cover the growth driven by enterprise deals and the value of its Digital Health Platform. Financial results will be released prior to the call, with a question-and-answer segment to follow. Interested parties can join via toll-free and international dial-in numbers. A replay will be available until November 30, 2020.
OptimizeRx Corp. (Nasdaq: OPRX), a leader in digital health solutions, will participate in two investor conferences in November 2020. The events are the Roth Technology Virtual Conference on November 11 and the Stifel Midwest One-on-One Growth Conference on November 12. Management will engage in one-on-one meetings with institutional investors to discuss the company’s anticipated record revenue exceeding $10 million for Q3 2020, representing over 100% year-over-year growth. This growth stems from strong enterprise deals and programs enhancing value for life science customers.
OptimizeRx Corp. (Nasdaq: OPRX) reported impressive preliminary revenue for Q3 2020, exceeding $10 million, a 100% year-over-year increase. The company anticipates positive non-GAAP net income for the quarter due to organic growth driven by enterprise deals and tactical programs. The revenue for the first nine months surged over 53% to $26.4 million. The CEO noted a strategic focus on expanding physician and patient reach, attributing growth to increased enterprise agreements. Full Q3 results will be disclosed in early November.
OptimizeRx Corp (Nasdaq: OPRX) is set to resume its webinar series, focusing on improving medication launches with industry experts. Scheduled for September 24 at 1:00 p.m. ET, the webinar will address patient adherence challenges due to side effects of new medications. In collaboration with the Digital Health Coalition and Diligent Health Solutions, the session will explore a successful patient engagement case study and innovative strategies for life science companies. The webinar is free to industry professionals and aims to enhance patient outcomes.
OptimizeRx Corp. (Nasdaq: OPRX) has partnered with Epion Health to enhance patient access to savings programs prior to medical appointments. Patients using Epion’s digital check-in can now connect with OptimizeRx for real-time medication cost-saving opportunities based on their health records. This integration aims to facilitate conversations about affordability between patients and providers, thereby improving treatment outcomes. The partnership is expected to launch next month, expanding services to health systems nationwide, benefiting over 10 million patient appointments annually.
